Translational Oncogenomics

Oct 16, 2024 | redjournal.org | Mark Reardon |Translational Oncogenomics |Daniel E. Spratt |Alex Hakansson

Keywordsprostate cancerbiochemical recurrencehypoxiaandrogen deprivation therapyIntroductionProstate cancer (PCa) is diagnosed in 1.4 million men globally each year and causes 375,000 deaths, making PCa the second-most common cancer and fifth-most common cause of cancer death in men [1]. Patients are stratified by clinical parameters such as blood prostate-specific antigen (PSA) levels, tumour T-stage and histopathological Gleason grade group into low, intermediate, and high-risk PCa [2].